First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors - Concepedia

Concepedia

Publication | Open Access

First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors

DOI Full Paper Access

22

Citations

25

References

2023

Year

Rom S. Leidner, Kevin C. Conlon, Douglas G. McNeel, Andrea Wang‐Gillam, Sumati Gupta, Robert Wesolowski, Monica Chaudhari, Nadia B. Hassounah, Jong Bong Lee, Lang Ho Lee,

Journal for ImmunoTherapy of Cancer

Abstract

NCT02452268.

References

	Year	Citations

Page 1